About TRIGR Therapeutics
TRIGR Therapeutics is a company based in Irvine (United States) founded in 2018 was acquired by Compass Therapeutics in May 2021. TRIGR Therapeutics has raised $5 million across 1 funding round from investors including Compass Therapeutics and Handok. TRIGR Therapeutics operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter Irvine, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$5 M (USD)
in 1 rounds
-
Latest Funding Round
$5 M (USD), Series A
Apr 25, 2019
-
Investors
Compass Therapeutics
& 1 more
-
Employee Count
Not available
-
Acquired by
Compass Therapeutics
(May 13, 2021)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of TRIGR Therapeutics
TRIGR Therapeutics has successfully raised a total of $5M through 1 strategic funding round. The most recent funding activity was a Series A round of $5 million completed in April 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in TRIGR Therapeutics
TRIGR Therapeutics has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Compass Therapeutics and Handok.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Pharmaceuticals, medical devices, and healthcare products are developed and marketed.
|
Locked | Locked | Locked | |
|
Therapeutic antibodies for cancer treatment are discovered and developed.
|
Locked | Locked | Locked |
Investor details for TRIGR Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by TRIGR Therapeutics
Investment portfolio details for TRIGR Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - TRIGR Therapeutics
Detailed financials for TRIGR Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Trigr Therapeutics Comparisons
Peer comparison for TRIGR Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of TRIGR Therapeutics
TRIGR Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
Detailed competitors of TRIGR Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Trigr Therapeutics
Complete news archive for TRIGR Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about TRIGR Therapeutics
TRIGR Therapeutics was founded in 2018 and raised its 1st funding round 1 year after it was founded.
TRIGR Therapeutics is headquartered in Irvine, United States. It is registered at Irvine, California, United States.
TRIGR Therapeutics is a funded company, having raised a total of $5M across 1 funding round to date.
TRIGR Therapeutics is developing small molecule-based therapeutics for the treatment of cancer. The companys lead product candidate is targeting vascular endothelial growth factor (VEGF) signaling pathway and DLL4 both of which play an important role in vascular development and tumor angiogenesis. It is used for the treatment of gastric cancer and other solid tumors and is Phase 1 clinical trials. The company is also developing other products for the treatment of multiple myeloma and other solid tumors.
TRIGR Therapeutics's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
TRIGR Therapeutics has 2 investors. Key investors include Compass Therapeutics, and Handok.